TL;DR
In vivo results demonstrated that NT supplementation attenuated repetitive behaviors and improved social interactions in the BTBR cohort, revealing pronounced sex-dimorphic responsiveness.
Key links between peripheral protein dysregulation and neuronal function and behavior are revealed, offering new insights into systemic contributions to ASD pathophysiology and highlighting potential therapeutic targets for mitigating symptom severity.
The evidence suggests that myelin-related pathways represent a common point of vulnerability across disorders and may offer a potential target for intervention, integrating findings from both animal models and human research.
Germline heterozygous TCF4 LOF, which models PTHS, does not appear to significantly affect the astrocyte lineage at the cell population level, and germline heterozygous Tcf4 LOF did not result in misallocation of ventrally derived astrocytes into the dorsal cortex.
This study confirmed that promoting inflammation resolution with MR-39 can open new therapeutic options for ASD and that this compound has potential as a drug.
Integrative pathogenetic mechanisms of ASD are explored, encompassing prenatal viral exposure, alterations in serotonin and oxytocin signaling pathways, regulation of N-methyl-D-aspartate receptors, SHANK proteins, and members of the Solute Carrier protein family.
How human cellular models have advanced basic and translational research in ASD is examined and key cellular and molecular convergent phenotypes that have emerged are identified.